Peptilogics Raises $78M in Oversubscribed Series B2 to Advance PLG0206

Deal Summary

Peptilogics completed an oversubscribed $78M Series B2 financing to support Phase 2/3 trials of zaloganan (PLG0206) for prosthetic joint infections. The round was led by Presight Capital, Thiel Bio and Founders Fund, with participation from AMR Action Fund, Narya Capital and Beyond Ventures.